144675-97-8 | Pixantrone dimaleate

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥95%	in stock	$42.00	$29.00
5mg	98%(HPLC)	in stock	$60.00	$42.00
25mg	98%(HPLC)	in stock	$150.00	$105.00
100mg	98%(HPLC)	in stock	$440.00	$308.00

Description

• Catalog Number: AA72335
• Chemical Name: Pixantrone dimaleate
• CAS Number: 144675-97-8
• Molecular Formula: C25H27N5O10
• Molecular Weight: 557.5094
• MDL Number: MFCD00920108
• SMILES: OC(=O)/C=C\C(=O)O.OC(=O)/C=C\C(=O)O.NCCNc1ccc(c2c1C(=O)c1cnccc1C2=O)NCCN

Computed Properties

• Complexity: 591
• Covalently-Bonded Unit Count: 3
• Defined Bond Stereocenter Count: 2
• Heavy Atom Count: 40
• Hydrogen Bond Acceptor Count: 15
• Hydrogen Bond Donor Count: 8
• Rotatable Bond Count: 10

Literature

• Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis.

  Journal of neuroimmunology 20130515

• The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

  The Journal of pharmacology and experimental therapeutics 20130201

• Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

  The Lancet. Oncology 20120701

• Pixantrone: a new agent for relapsed aggressive lymphomas.

  The Lancet. Oncology 20120701

• Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.

  Cancer 20111115

• Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

  Expert opinion on drug metabolism & toxicology 20111101

• Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.

  Leukemia & lymphoma 20110401

• DNA binding by pixantrone.

  Organic & biomolecular chemistry 20101207

• New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

  Journal of medicinal chemistry 20101014

• Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.

  Expert opinion on pharmacotherapy 20100801

• Lymphoma researchers in search of molecular targets.

  Journal of the National Cancer Institute 20100721

• Pixantrone maleate for non-Hodgkin's lymphoma.

  Drugs of today (Barcelona, Spain : 1998) 20091101

• Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.

  Future oncology (London, England) 20090501

• CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.

  Electrophoresis 20090401

• Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.

  Molecular pharmacology 20080701

• Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats.

  Journal of immunology (Baltimore, Md. : 1950) 20080215

• Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.

  Expert opinion on investigational drugs 20071001

• Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.

  Investigational new drugs 20070601

• Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

  Nucleic acids research 20070601

• A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20070201

• EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.

  Clinical lymphoma & myeloma 20060901

• Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis.

  Journal of neuroimmunology 20051101

• The role of pixantrone in the treatment of non-Hodgkin's lymphoma.

  Expert opinion on investigational drugs 20050801

• Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.

  Journal of the neurological sciences 20040815

• Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

  Journal of neuroimmunology 20040601

• A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.

  Expert opinion on pharmacotherapy 20040401

• Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

  Haematologica 20030801

• Pixantrone (Novuspharma).

  IDrugs : the investigational drugs journal 20030501

• Solid-state characterization of a novel chemotherapeutic drug.

  Journal of pharmaceutical sciences 20030301

• Characterization of anthracenediones and their photoaffinity analogs.

  Biochemical pharmacology 20020315

• Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity.

  Tumori 20010101

• Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.

  Molecular pharmacology 19950701